Literature DB >> 29345523

Hexim1, an RNA-controlled protein hub.

Annemieke A Michels1, Olivier Bensaude1.   

Abstract

Hexim1 acts as a tumor suppressor and is involved in the regulation of innate immunity. It was initially described as a non-coding RNA-dependent regulator of transcription. Here, we detail how 7SK RNA binds to Hexim1 and turns it into an inhibitor of the positive transcription elongation factor (P-TEFb). In addition to its action on P-TEFb, it plays a role in a variety of different mechanisms: it controls the stability of transcription factor components and assists binding of transcription factors to their targets.

Entities:  

Keywords:  7SK; CDK9; NEAT1; P-TEFb; eukaryotic transcription; innate immunity; melanoma; nucleotide depletion; transcription regulation; transcriptional elongation

Mesh：

Substances：

Year:  2018        PMID： 29345523      PMCID： PMC6104690          DOI： 10.1080/21541264.2018.1429836

Source DB:  PubMed          Journal:  Transcription        ISSN： 2154-1272


  96 in total

1.  Vascular endothelial growth factor gene regulation by HEXIM1 in heart.

Authors:  Atsushi Asakura
Journal:  Circ Res       Date:  2008-02-29       Impact factor: 17.367

2.  DDX6 transfers P-TEFb kinase to the AF4/AF4N (AFF1) super elongation complex.

Authors:  Fabian Mück; Silvia Bracharz; Rolf Marschalek
Journal:  Am J Blood Res       Date:  2016-09-15

Review 3.  Disorder-function relationships for the cell cycle regulatory proteins p21 and p27.

Authors:  Diana M Mitrea; Mi-Kyung Yoon; Li Ou; Richard W Kriwacki
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

4.  Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes.

Authors:  Sebastian Schröder; Sungyoo Cho; Lei Zeng; Qiang Zhang; Katrin Kaehlcke; Lily Mak; Joann Lau; Dwayne Bisgrove; Martina Schnölzer; Eric Verdin; Ming-Ming Zhou; Melanie Ott
Journal:  J Biol Chem       Date:  2011-11-14       Impact factor: 5.157

5.  The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1.

Authors:  Bryan M Wittmann; Koh Fujinaga; Huayun Deng; Ndiya Ogba; Monica M Montano
Journal:  Oncogene       Date:  2005-08-25       Impact factor: 9.867

6.  Crystal structure of HIV-1 Tat complexed with human P-TEFb.

Authors:  Tahir H Tahirov; Nigar D Babayeva; Katayoun Varzavand; Jeffrey J Cooper; Stanley C Sedore; David H Price
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

7.  BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.

Authors:  Georg E Winter; Andreas Mayer; Dennis L Buckley; Michael A Erb; Justine E Roderick; Sarah Vittori; Jaime M Reyes; Julia di Iulio; Amanda Souza; Christopher J Ott; Justin M Roberts; Rhamy Zeid; Thomas G Scott; Joshiawa Paulk; Kate Lachance; Calla M Olson; Shiva Dastjerdi; Sophie Bauer; Charles Y Lin; Nathanael S Gray; Michelle A Kelliher; L Stirling Churchman; James E Bradner
Journal:  Mol Cell       Date:  2017-06-29       Impact factor: 17.970

8.  SIRT7-dependent deacetylation of CDK9 activates RNA polymerase II transcription.

Authors:  Maximilian F Blank; Sifan Chen; Fabian Poetz; Martina Schnölzer; Renate Voit; Ingrid Grummt
Journal:  Nucleic Acids Res       Date:  2017-03-17       Impact factor: 16.971

9.  HEXIM1 is a promiscuous double-stranded RNA-binding protein and interacts with RNAs in addition to 7SK in cultured cells.

Authors:  Qintong Li; Jeffrey J Cooper; Gary H Altwerger; Michael D Feldkamp; Madeline A Shea; David H Price
Journal:  Nucleic Acids Res       Date:  2007-03-29       Impact factor: 16.971

Review 10.  Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer.

Authors:  Ruichuan Chen; Jasper H N Yik; Qiao Jing Lew; Sheng-Hao Chao
Journal:  Biomed Res Int       Date:  2014-01-29       Impact factor: 3.411
View more
  7 in total

1.  Regulation of RNA polymerase II activity is essential for terminal erythroid maturation.

Authors:  Zachary C Murphy; Kristin Murphy; Jacquelyn Myers; Michael Getman; Tyler Couch; Vincent P Schulz; Kimberly Lezon-Geyda; Cal Palumbo; Hongxia Yan; Narla Mohandas; Patrick G Gallagher; Laurie A Steiner
Journal:  Blood       Date:  2021-11-04       Impact factor: 22.113

2.  Different views of the dynamic landscape covered by the 5'-hairpin of the 7SK small nuclear RNA.

Authors:  Karl Brillet; Denise Martinez-Zapien; Guillaume Bec; Eric Ennifar; Anne-Catherine Dock-Bregeon; Isabelle Lebars
Journal:  RNA       Date:  2020-05-19       Impact factor: 4.942

3.  P-TEFb Activation by RBM7 Shapes a Pro-survival Transcriptional Response to Genotoxic Stress.

Authors:  Andrii Bugai; Alexandre J C Quaresma; Caroline C Friedel; Tina Lenasi; Robert Düster; Christopher R Sibley; Koh Fujinaga; Petra Kukanja; Thomas Hennig; Melanie Blasius; Matthias Geyer; Jernej Ule; Lars Dölken; Matjaž Barborič
Journal:  Mol Cell       Date:  2019-02-26       Impact factor: 17.970

4.  de novo MEPCE nonsense variant associated with a neurodevelopmental disorder causes disintegration of 7SK snRNP and enhanced RNA polymerase II activation.

Authors:  Pauline E Schneeberger; Tatjana Bierhals; Axel Neu; Maja Hempel; Kerstin Kutsche
Journal:  Sci Rep       Date:  2019-08-29       Impact factor: 4.379

5.  HEXIM1 Diffusion in the Nucleus Is Regulated by Its Interactions with Both 7SK and P-TEFb.

Authors:  Alessandro Furlan; Mariano Gonzalez-Pisfil; Aymeric Leray; Dorian Champelovier; Mélanie Henry; Corentin Le Nézet; Oliver Bensaude; Marc Lefranc; Thorsten Wohland; Bernard Vandenbunder; Gabriel Bidaux; Laurent Héliot
Journal:  Biophys J       Date:  2019-09-20       Impact factor: 4.033

6.  Tip110 Expression Facilitates the Release of HEXIM1 and pTEFb from the 7SK Ribonucleoprotein Complex Involving Regulation of the Intracellular Redox Level.

Authors:  Ying Liu; Lu Li; Khalid Timani; Carl White; Johnny J He
Journal:  Aging Dis       Date:  2021-12-01       Impact factor: 6.745

Review 7.  Targeting CDK9 for Anti-Cancer Therapeutics.

Authors:  Ranadip Mandal; Sven Becker; Klaus Strebhardt
Journal:  Cancers (Basel)       Date:  2021-05-01       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.